The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Biomarkers and surrogate markers: An FDA perspective
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Echt, D. S., Liebson, P. R., Mitchell, L. B., Peters, R. W., Obias-Manno, D., Barker, A. H., Arensberg, D., Baker, A., Friedman, L., Greene, H. L., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103213241201 · Cited by 3,253
Surrogate End Points in Clinical Trials: Are We Being Misled?
Fleming, T. R., & DeMets, D. L. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-7-199610010-00011 · Cited by 1,651
Effect of Fluoride Treatment on the Fracture Rate in Postmenopausal Women with Osteoporosis
Riggs, B. L., Hodgson, S. F., O'Fallon, W. M., Chao, E. Y. S., Wahner, H. W., Muhs, J. M., Cedel, S. L., & Melon, L. J. (1990) · New England Journal of Medicine · doi:10.1056/nejm199003223221203 · Cited by 1,088
Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”
(1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00022-0 · Cited by 666
End Points and United States Food and Drug Administration Approval of Oncology Drugs
Johnson, J. R., Williams, G., & Pazdur, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.072 · Cited by 479
An [18F]dopa–PET and clinical study of the rate of progression in Parkinson’s disease
Morrish, P. K., Sawle, G. V., & Brooks, D. J. (1996) · Brain · doi:10.1093/brain/119.2.585 · Cited by 366
Fox, N. C., Cousens, S., Scahill, R., Harvey, R. J., & Rossor, M. N. (2000) · Archives of Neurology · doi:10.1001/archneur.57.3.339 · Cited by 360
Are Surrogate Markers Adequate to Assess Cardiovascular Disease Drugs?
Temple, R. (1999) · JAMA · doi:10.1001/jama.282.8.790 · Cited by 337
Slowing the progression of Alzheimer disease: methodologic issues.
Leber, P. D. (1997) · PubMed · Cited by 104
Cited by
Relation of Visual Function to Retinal Nerve Fiber Layer Thickness in Multiple Sclerosis
FISHER, J., JACOBS, D., MARKOWITZ, C., GALETTA, S., VOLPE, N., NANOSCHIAVI, M., BAIER, M., FROHMAN, E., WINSLOW, H., & FROHMAN, T. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2005.10.040 · Cited by 658
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives
Hampel, H., Frank, R., Broich, K., Teipel, S. J., Katz, R. G., Hardy, J., Herholz, K., Bokde, A. L. W., Jessen, F., Hoessler, Y. C., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3115 · Cited by 631
Self-citationAcute Stroke Imaging Research Roadmap
Wintermark, M., Albers, G. W., Alexandrov, A. V., Alger, J. R., Bammer, R., Baron, J.-C., Davis, S., Demaerschalk, B. M., Derdeyn, C. P., Donnan, G. A., et al. (2008) · Stroke · doi:10.1161/strokeaha.107.512319 · Cited by 423
Ahmad, A., Imran, M., & Ahsan, H. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061630 · Cited by 386
Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift
Golde, T. E., Schneider, L. S., & Koo, E. H. (2011) · Neuron · doi:10.1016/j.neuron.2011.01.002 · Cited by 382
Metadata
- Authors
- Katz, R.
- Venue
- NeuroRX
- Published
- 2004-04
- Volume
- 1
- Issue
- 2
- Pages
- 189-195
- ISSN
- 1545-5343 (ISSN-L)
- OpenAlex
- W2080763041
- Cited by
- 347
- References
- 12
- FWCI
- 10.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Biomarkers and surrogate markers: An FDA perspective. https://app.cochat.ai/papers/10.1602/neurorx.1.2.189
- The paper
- Katz, R. (2004). Biomarkers and surrogate markers: An FDA perspective. NeuroRX. https://doi.org/10.1602/neurorx.1.2.189
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.